Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Soterix Medical
With
Columbia University
This trial is a biomarker development study. The effects of various doses of ketamine infusion on depressive symptoms and EEG signals in patients with unipolar depression will be analyzed.
Age
18–59
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Physically healthy patients who meet DMS-5 criteria for a major depressive episode (MDE) in the context of MDD and who score at least 22 on the Montgomery-Åsberg Depression Rating Scale (MADRS)
If taking antidepressants, dose is stable for at least 6 weeks.
You may not be if
Lifetime history of bipolar disorder, schizoaffective disorder, schizophrenia, or any other psychotic disorder, including MDD with psychotic features
A first-degree relative with bipolar disorder, schizoaffective disorder, or schizophrenia, with the potential participant younger than 33 years (i.e., still at age of risk for a psychotic disorder)
Receipt of electroconvulsive therapy within 3 months of enrolling in the study
History of IV drug use
Nonresponse or intolerance to ketamine administered either clinically or as part of a prior research study
Pregnancy, planning to conceive, or sexually active but not using adequate birth control.
Actively suicidal (CSSRS≥3)
No antipsychotics or medications (e.g. benzodiazepines, anti-epileptics) that are likely to interact with GABA or glutamate,